Surrogate end points in clinical research: hazardous to your health.

  title={Surrogate end points in clinical research: hazardous to your health.},
  author={D. Grimes and K. Schulz},
  journal={Obstetrics and gynecology},
  volume={105 5 Pt 1},
  • D. Grimes, K. Schulz
  • Published 2005
  • Medicine
  • Obstetrics and gynecology
  • Surrogate end points in clinical research pose real danger. A surrogate end point is an outcome measure, commonly a laboratory test, that substitutes for a clinical event of true importance. Resistance to activated protein C, for example, has been used as a surrogate for venous thrombosis in women using oral contraceptives. Other examples of inappropriate surrogate end points in contraception include the postcoital test instead of pregnancy to evaluate new spermicides, breakage and slippage… CONTINUE READING
    121 Citations
    The use and abuse of surrogate endpoints in clinical research in transfusion medicine
    • 9
    Surrogate end points in women's health research: science, protoscience, and pseudoscience.
    • 34
    Meta-analysis for the evaluation of surrogate endpoints in cancer clinical trials
    • 66
    Changes in surrogate outcomes can be translated into clinical outcomes using a Monte Carlo model.
    • 15
    Evaluation of Benefit-Risk
    • 12


    Surrogate End Points in Clinical Trials: Are We Being Misled?
    • 1,387
    • PDF
    Clinical trial end points: on the road to nowhere?
    • 42
    Surrogate endpoints in clinical trials: definition and operational criteria.
    • 1,608
    The promise and peril of surrogate end points in cancer research
    • 135
    • PDF
    A perfect correlate does not a surrogate make
    • 137
    Statistical issues for HIV surrogate endpoints: point/counterpoint. An NIAID workshop.
    • 37
    • PDF
    Oral contraceptives and blood coagulation: a critical review.
    • E. Mammen
    • Medicine
    • American journal of obstetrics and gynecology
    • 1982
    • 115
    Sex hormone--binding globulin--a surrogate marker for the prothrombotic effects of combined oral contraceptives.
    • 36